AUB ScholarWorks

Breast Cancer Patients With 10 or More Involved Axillary Lymph Nodes Treated by Multimodality Therapy: Influence of Clinical Presentation on Outcome

Show simple item record

dc.contributor.author Geara F.B.
dc.contributor.author Nasr E.
dc.contributor.author Tucker S.L.
dc.contributor.author Charafeddine M.
dc.contributor.author Dabaja B.
dc.contributor.author Eid T.
dc.contributor.author Abbas J.
dc.contributor.author Salem Z.
dc.contributor.author Shamseddine A.
dc.contributor.author Issa P.
dc.contributor.author El Saghir N.
dc.contributor.editor
dc.date Jun-2007
dc.date.accessioned 2017-10-05T16:07:20Z
dc.date.available 2017-10-05T16:07:20Z
dc.date.issued 2007
dc.identifier 10.1016/j.ijrobp.2006.12.027
dc.identifier.isbn
dc.identifier.issn 03603016
dc.identifier.uri http://hdl.handle.net/10938/19731
dc.description.abstract Purpose: To analyze tumor control and survival for breast cancer patients with 10 or more positive lymph nodes without systemic disease, treated by adjuvant radiation alone or combined-modality therapy. Methods and Materials: We reviewed the records of 309 consecutive patients with these characteristics who received locoregional radiotherapy (RT) at our institution. The majority of patients had clinical Stage II or IIIA-B disease (43percent and 48percent, respectively). The median number of positive axillary lymph nodes was 15 (range, 10-78). Adjuvant therapy consisted of RT alone, with or without chemotherapy, tamoxifen, and-or ovarian castration. Results: The overall 5-year and 10-year disease-free survival (DFS) rates were 20percent and 7percent, respectively. Median DFS was higher for patients with Stage I-II compared with those with Stage IIIABC (28 vs. 19 months; p = 0.006). Median DFS for patients aged ≤35 years was lower than that of older patients (12 vs. 24 months; p 0.0001). Patients treated with a combination therapy had a higher 5-year DFS rate compared with those treated by RT alone (26percent vs. 11percent; p = 0.03). In multivariate analysis, clinical stage (III vs. I, II; relative risk = 1.8, p = 0.002) and age (≤35 vs. others; relative risk = 2.6, p 0.001) were found to be independent variables for DFS. Conclusion: This retrospective data analysis identified young age and advanced clinical stage as pertinent and independent clinical prognostic factors for breast cancer patients with advanced axillary disease (10 or more involved nodes). These factors can be used for further prognostic classification. © 2007 Elsevier Inc. All rights reserved.
dc.format.extent
dc.format.extent Pages: (364-369)
dc.language English
dc.publisher NEW YORK
dc.relation.ispartof Publication Name: International Journal of Radiation Oncology Biology Physics; Publication Year: 2007; Volume: 68; no. 2; Pages: (364-369);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Breast Cancer Patients With 10 or More Involved Axillary Lymph Nodes Treated by Multimodality Therapy: Influence of Clinical Presentation on Outcome
dc.type Article
dc.contributor.affiliation Geara, F.B., Department of Radiation Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Nasr, E., Department of Radiation Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Tucker, S.L., Department of Biomathematics, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, United States
dc.contributor.affiliation Charafeddine, M., Department of Epidemiology and Biostatistics, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Dabaja, B., Department of Radiation Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Eid, T., Department of Radiation Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Abbas, J., Department of General Surgery, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Salem, Z., Department of Medical Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Shamseddine, A., Department of Medical Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation Issa, P., Department of Radiation Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.affiliation El Saghir, N., Department of Medical Oncology, The American University, Beirut Medical Center, Beirut, Lebanon
dc.contributor.authorAddress Geara, F.B.; Department of Radiation Oncology, The American University, Beirut Medical Center, Beirut, Lebanon; email: fg00@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Surgery; Division: General Surgery;
dc.contributor.authorDepartment Surgery
dc.contributor.authorDivision General Surgery
dc.contributor.authorEmail fg00@aub.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Geara, FB
dc.contributor.authorInitials Nasr, E
dc.contributor.authorInitials Tucker, SL
dc.contributor.authorInitials Charafeddine, M
dc.contributor.authorInitials Dabaja, B
dc.contributor.authorInitials Eid, T
dc.contributor.authorInitials Abbas, J
dc.contributor.authorInitials Salem, Z
dc.contributor.authorInitials Shamseddine, A
dc.contributor.authorInitials Issa, P
dc.contributor.authorInitials El Saghir, N
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Geara, FB (reprint author), Amer Univ Beirut, Dept Radiat Oncol, Med Ctr, 3 Dag Hammarskjold Plaza,8th Floor, New York, NY 10017 USA.
dc.contributor.authorResearcherID Dabaja, Bouthaina-A-9970-2009
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Buchholz TA, 2004, J CLIN ONCOL, V22, p16S; CARTER CL, 1989, CANCER, V63, P181, DOI 10.1002-1097-0142(19890101)63:1181::AID-CNCR28206301293.0.CO;2-H; Abe O, 2005, LANCET, V366, P2087; Coombes RC, 2005, ANN ONCOL, V16, P726, DOI 10.1093-annonc-mdi166; Diab SG, 1998, J CLIN ONCOL, V16, P1655; DONEGAN WL, 1978, SEMIN ONCOL, V5, P373; Early Breast Canc Trialists Collaborat, 2000, LANCET, V355, P1757, DOI 10.1016-S0140-6736(00)02263-7; Abe O, 2005, LANCET, V365, P1687; Farquhar CM., 2005, COCHRANE DB SYST REV, DOI DOI 10.1002-14651858.CD004143.PUB2; FISHER ER, 1975, CANCER, V36, P1, DOI 10.1002-1097-0142(197507)36:11::AID-CNCR28203601023.0.CO;2-4; FOWBLE B, 1988, J CLIN ONCOL, V6, P1107; Hortobagyi GN, 2000, J NATL CANCER I, V92, P225, DOI 10.1093-jnci-92.3.225; Jabro G, 1999, INT J RADIAT ONCOL, V44, P273, DOI 10.1016-S0360-3016(99)00009-7; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002-1097-0142(19800615)45:122917::AID-CNCR28204512033.0.CO;2-M; Nitz UA, 2005, LANCET, V366, P1935, DOI 10.1016-S0140-6736(05)67784-7; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056-NEJM199710023371401; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056-NEJM199710023371402; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016-S0140-6736(98)01350-6; Schrama JG, 2002, ANN ONCOL, V13, P689, DOI 10.1093-annonc-mdf203; STROM EA, 1991, INT J RADIAT ONCOL, V21, P319; Tallman MS, 2003, NEW ENGL J MED, V349, P17, DOI 10.1056-NEJMoa030684; Zander AR, 2004, J CLIN ONCOL, V22, P2273, DOI 10.1200-JCO.2004.07.028
dc.description.citedCount 3
dc.description.citedTotWOSCount 4
dc.description.citedWOSCount 3
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden IOBPD
dc.identifier.pubmedID 17324529
dc.identifier.scopusID 34247846125
dc.identifier.url
dc.publisher.address 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Int. J. Radiat. Oncol. Biol. Phys.
dc.relation.ispartOfIssue 2
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle International Journal of Radiation Oncology Biology Physics
dc.relation.ispartofPubTitleAbbr Int. J. Radiat. Oncol. Biol. Phys.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 68
dc.source.ID WOS:000246730000008
dc.type.publication Journal
dc.subject.otherAuthKeyword Advanced disease
dc.subject.otherAuthKeyword Breast cancer
dc.subject.otherAuthKeyword Clinical presentation
dc.subject.otherChemCAS cyclophosphamide, 50-18-0
dc.subject.otherChemCAS doxorubicin, 23214-92-8, 25316-40-9
dc.subject.otherChemCAS fluorouracil, 51-21-8
dc.subject.otherChemCAS methotrexate, 15475-56-6, 59-05-2, 7413-34-5
dc.subject.otherChemCAS tamoxifen, 10540-29-1
dc.subject.otherIndex Chemotherapy
dc.subject.otherIndex Diseases
dc.subject.otherIndex Living systems studies
dc.subject.otherIndex Multivariable control systems
dc.subject.otherIndex Tumors
dc.subject.otherIndex Advanced diseases
dc.subject.otherIndex Breast cancer
dc.subject.otherIndex Clinical presentation
dc.subject.otherIndex Multivariate analysis
dc.subject.otherIndex Patient treatment
dc.subject.otherIndex cyclophosphamide
dc.subject.otherIndex doxorubicin
dc.subject.otherIndex fluorouracil
dc.subject.otherIndex methotrexate
dc.subject.otherIndex tamoxifen
dc.subject.otherIndex adult
dc.subject.otherIndex aged
dc.subject.otherIndex article
dc.subject.otherIndex axillary lymph node
dc.subject.otherIndex breast cancer
dc.subject.otherIndex cancer combination chemotherapy
dc.subject.otherIndex cancer control
dc.subject.otherIndex cancer patient
dc.subject.otherIndex cancer radiotherapy
dc.subject.otherIndex cancer risk
dc.subject.otherIndex cancer survival
dc.subject.otherIndex castration
dc.subject.otherIndex female
dc.subject.otherIndex human
dc.subject.otherIndex major clinical study
dc.subject.otherIndex medical record review
dc.subject.otherIndex multimodality cancer therapy
dc.subject.otherIndex multivariate analysis
dc.subject.otherIndex priority journal
dc.subject.otherIndex prognosis
dc.subject.otherIndex survival rate
dc.subject.otherIndex survival time
dc.subject.otherIndex Adult
dc.subject.otherIndex Aged
dc.subject.otherIndex Aged, 80 and over
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Axilla
dc.subject.otherIndex Breast Neoplasms
dc.subject.otherIndex Combined Modality Therapy
dc.subject.otherIndex Disease-Free Survival
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Lymphatic Metastasis
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Neoplasm Staging
dc.subject.otherIndex Prognosis
dc.subject.otherIndex Radiotherapy, Adjuvant
dc.subject.otherIndex Regression Analysis
dc.subject.otherKeywordPlus HIGH-DOSE CHEMOTHERAPY
dc.subject.otherKeywordPlus STEM-CELL TRANSPLANTATION
dc.subject.otherKeywordPlus RANDOMIZED-TRIAL
dc.subject.otherKeywordPlus ADJUVANT CHEMOTHERAPY
dc.subject.otherKeywordPlus POSTOPERATIVE RADIOTHERAPY
dc.subject.otherKeywordPlus PREMENOPAUSAL WOMEN
dc.subject.otherKeywordPlus 15-YEAR SURVIVAL
dc.subject.otherKeywordPlus SUPPORT
dc.subject.otherKeywordPlus MANAGEMENT
dc.subject.otherKeywordPlus RECURRENCE
dc.subject.otherWOS Oncology
dc.subject.otherWOS Radiology, Nuclear Medicine and Medical Imaging


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account